Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today financial results for the quarter ended June 30, 2007 and provided financial and operational guidance for fiscal year 2007.
“Molecular Insight has had a very productive second quarter in progressing our robust portfolio of promising and innovative molecular imaging pharmaceuticals and targeted radiotherapeutics for cancer,” said David S. Barlow, Chairman and CEO of Molecular Insight. “Our clinical development programs are all on or ahead of plan. We have initiated the planned pivotal registration trial for Zemiva and are actively enrolling patients on schedule. Our Phase 1 of a planned Phase 1/2 trial for AzedraTM has begun dosing the second patient cohort ahead of schedule, and, in the Onalta™ development program, we completed the technology transfer from Tyco/Mallinckrodt to two manufacturing sites, ahead of schedule. Our Solazed™ and Trofex development programs remain on track.”
